Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018
Authors:
- Claudio VelatiCVClaudio Velati
- Luisa RomanòLRLuisa Romanò
- Ilaria PatiIlaria Pati
- Giuseppe MaranoGMGiuseppe Marano
- Vanessa PiccininiVPVanessa Piccinini
- Liviana CatalanoLCLiviana Catalano
- Simonetta PupellaSPSimonetta Pupella
- Francesca MasielloFMFrancesca Masiello
- Giulio PisaniGPGiulio Pisani
- Giuliano GrazziniGGGiuliano Grazzini
- 1 November 2019
- journal article
- research article
- Vol. 17 (6) , 409-417
Abstract
In Italy, the use of nucleic acid testing for hepatitis B virus (HBV) in donor screening has allowed the detection of infections in the window phase, as well as the presence of occult infections which could potentially be transmitted. The aim of this study was to analyse the trends of epidemiological data focused on HBV infection in blood donors and to estimate the residual risk of transmitting HBV from both the window phase and occult infection over a 10-year period in Italy. Data were obtained from the Italian Haemovigilance System which includes the results of screening tests for transfusion transmissible infections. During the period of this survey (2009-2018), the molecular methods used for HBV screening were transcription-mediated amplification and polymerase chain reaction tests. Prevalence and incidence were calculated. The residual risk was estimated by applying the incidence-window period model for acute cases and a more recently reported model for estimating the risk due to occult infections. A total of 17,424,535 blood donors and 30,842,794 donations were tested for HBV. Altogether, 6,250 donors tested positive for HBV markers: 4,782 (175.6×105) were first time donors and 1,468 (10.0×105) were repeat donors. The prevalence of HBV markers in first time donors was 275.9×105 in 2009, declining to 143.6×105 in 2018. The incidence of new infections was 3.37×105 in 2009 and 2.17×105 in 2018. The overall residual risk for HBV amounted to 1 in 2,566,854 donations calculated as the sum of risks of both acute infections in the window period (1 in 5,835,306 donations) and occult infections (1 in 4,582,270 blood units). In Italy, the residual risk of transfusing a blood unit infected with HBV, both from window phase and occult infections, is currently very low, amounting to levels that can be considered tolerable.Keywords
This publication has 26 references indexed in Scilit:
- Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV InfectionClinical Infectious Diseases, 2011
- Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithmsTransfusion, 2010
- Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusionTransfusion, 2009
- Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback programTransfusion, 2007
- Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virusInternal Medicine Journal, 2005
- A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donorsTransfusion, 2005
- Cancer: science and society and the communication of riskBMJ, 1996
- The Risk of Transfusion-Transmitted Viral InfectionsNew England Journal of Medicine, 1996
- Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United StatesNew England Journal of Medicine, 1995
- Vaccination against hepatitis B: the Italian strategyVaccine, 1993